Premium
SURVIVAL STUDIES ON A COMMERCIAL PREPARATION OF INTRAVENOUS HUMAN GAMMAGLOBULIN LABELLED WITH 131 I
Author(s) -
WELLS J. VIVIAN,
PENNY R.
Publication year - 1969
Publication title -
australasian annals of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 0571-9283
DOI - 10.1111/imj.1969.18.3.271
Subject(s) - catabolism , multiple myeloma , gamma globulin , medicine , endocrinology , gastroenterology , chemistry , immunology , antibody , metabolism
SUMMARY The biological activity of a new preparation of human gammaglobulin (HGG) was assessed by performing metabolic protein survival studies with 131 I‐labelled HGG(C.S.L.). The subjects included two normal controls and one patient each with cirrhosis, G‐myeloma and hypogammaglobulinæmia. In addition to IgG, the HGG(C.S.L.) contained 33 mg/100 ml IgM, less than 10 mg/100 ml IgA, and no detectable complement (as C′3) when assessed by immunological techniques. There were no reactions to the injected 131 I‐HGG(C.S.L.), but all subjects showed significantly increased urinary excretion of free 131 I in the initial 48 hours of the turnover study. This suggested that a proportion of IgG molecules in the HGG(C.S.L.) had been structurally altered during preparation. The catabolism of HGG(C.S.L.) was abnormally increased in normal controls, with a short half‐life and increased fractional turnover rate. In hypogammaglobulinæmia, both the plasma half‐life and fractional turnover rate were normal, and further studies and clinical trials on the efficacy of this preparation in this disease are warranted.